<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;SMAD4&lt;/i&gt;
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        SMAD4
       </i>
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         SMAD4
        </i>
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Chung, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kiley Delgado, MS, CGC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Thomas Lamont, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne Slavotinek, MBBS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 09, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H148095375">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This monograph summarizes the interpretation of germline testing of the
         <em>
          SMAD4
         </em>
         gene. It does
         <strong>
          not
         </strong>
         discuss indications for testing and is not intended to replace clinical judgment in the decision to test or the care of the tested individual. These subjects are discussed separately [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1016660184">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H2761619754">
         <span class="h2">
          How to read the report
         </span>
         <span class="headingEndMark">
          —
         </span>
         An approach to reviewing a genetic test report is summarized in the checklist  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Testing involves two steps: determining the genotype and interpreting the pathogenicity of the variant(s).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Determining the
         </strong>
         <strong>
          genotype
         </strong>
         – Identifies variants. Should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory if the results were obtained by direct-to-consumer testing or a research study and would impact clinical care (eg, positive finding, negative finding in an individual with a suspected juvenile polyposis syndrome [JPS] or hereditary hemorrhagic telangiectasia [HHT]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation
         </strong>
         – Determines pathogenicity of the variants identified. May require updating, especially for variants of uncertain significance (VUS).
        </p>
        <p>
        </p>
        <p>
         The table provides a glossary of genetic testing terms  (
         <a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3653542309">
         <span class="h2">
          Disease associations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic and likely pathogenic variants in
         <em>
          SMAD4
         </em>
         cause JPS and JP-HHT, an autosomal dominant disorder.
        </p>
        <p>
         The
         <em>
          SMAD4
         </em>
         gene encodes a cytoplasmic mediator of the transforming growth factor-beta (TGF-beta) signaling pathway.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intestinal tumors
         </strong>
         – JPS is characterized by the presence of multiple juvenile polyps in the colorectum. Most patients are symptomatic by age 20 years. Rectal bleeding is the most common presenting symptom. Other symptoms include abdominal pain due to obstruction from intussusception, diarrhea due to protein-losing enteropathy, and rectal prolapse of polyps.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Polyps usually begin to appear in the first decade of life, and patients can develop between five to hundreds of polyps in their lifetime. Polyps occur predominantly in the colorectum but can occur in the stomach, duodenum, jejunum, and ileum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with JPS are at increased risk for colorectal, small bowel, and gastric cancer. The cumulative risk of colorectal cancer is 17 to 22 percent by age 35 years and 68 percent by age 60 years [
         <a href="#rid2">
          2,3
         </a>
         ]. The mean age at colorectal cancer diagnosis in patients with JPS is 34 years. Individuals with JPS are also at increased risk for gastric and duodenal cancer, with an estimated lifetime risk of 11 to 20 percent [
         <a href="#rid2">
          2,4-6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Juvenile polyposis of infancy is a rare variant of JPS in which juvenile (hamartomatous) polyps occur in both the upper and lower gastrointestinal tract (including the small bowel) and polyps develop within the first few years of life. In the stomach, juvenile polyps can be more difficult to recognize and often resemble hyperplastic polyps or other hamartomatous gastric polyps. Symptoms include diarrhea, bleeding, and intussusception. Macrocephaly and hypotonia may also occur. Patients often die at an early age due to gastrointestinal complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HHT
         </strong>
         – Individuals with JPS due to pathogenic variants in
         <em>
          SMAD4
         </em>
         are considered to be at risk for HHT. It is estimated that 32 percent of individuals with
         <em>
          SMAD4
         </em>
         pathogenic variants will exhibit features of HHT, although the proportion may be considerably higher [
         <a href="#rid7">
          7
         </a>
         ]. JP-HHT is a juvenile polyposis-HHT overlap syndrome that accounts for approximately 1 percent of HHT cases. Individuals with HHT can develop telangiectasia or arteriovenous malformations (AVMs) of the skin, buccal mucosa, gastrointestinal tract, lung, liver, and brain. (See
         <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extraintestinal manifestations
         </strong>
         – Other conditions associated with JPS include cardiac (eg, mitral valve prolapse), vascular (eg, arterial aneurysms), skeletal, and cranial anomalies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3655772747">
         <span class="h1">
          IMPLICATIONS OF A PATHOGENIC OR LIKELY PATHOGENIC VARIANT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We consider all individuals with a pathogenic or likely pathogenic variant in
         <em>
          SMAD4
         </em>
         to be at risk for juvenile polyposis syndrome (JPS) and hereditary hemorrhagic telangiectasia (HHT), regardless of the initial reason for testing.
        </p>
        <p>
         Discussion should include the range of associated risks, possible interventions for surveillance or risk reduction, and implications for family members. (See
         <a class="local">
          'At-risk relatives'
         </a>
         below.)
        </p>
        <p>
         Counseling may require additional visits or referrals. While prompt follow-up is recommended, acting upon genetic test results is rarely an emergency; the individual can be reassured that management decisions can be deferred until questions are answered.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer
         </strong>
         – We adhere to National Comprehensive Cancer Network (NCCN) recommendations for cancer surveillance and risk reduction [
         <a href="#rid8">
          8
         </a>
         ]. Findings in family members (type of cancers, age of onset) may also inform surveillance (starting at an earlier age if a family member has an earlier age of onset).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HHT
         </strong>
         – We follow consensus guidelines for surveillance and evaluations related to HHT [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition to annual physical examination including a cardiovascular examination, we monitor a complete blood count annually to evaluate for iron deficiency anemia secondary to blood loss. Several evaluations and interventions are recommended to reduce the risk of JPS-associated cancers  (
         <a class="graphic graphic_algorithm graphicRef131006" href="/z/d/graphic/131006.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3878016914">
         <span class="h2">
          Colorectal polyps and cancer
         </span>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Colorectal cancer screening/surveillance:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Individuals with a pathogenic
         <em>
          SMAD4
         </em>
         variant should have a colonoscopy every one to three years, beginning at age 12 years or earlier in patients who present with symptoms. If polyps are found, colonoscopy should be repeated annually; otherwise, colonoscopy intervals can be increased to every one to three years [
         <a href="#rid5">
          5
         </a>
         ]. Polyps can usually be resected endoscopically.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Indications for colectomy and ileorectal anastomosis (IRA) or proctocolectomy and ileal pouch anal anastomosis include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe symptoms related to colonic polyps (eg, severe gastrointestinal bleeding)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Colorectal cancer, adenoma with high-grade dysplasia, or multiple adenomas &gt;6 mm
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Marked increases in polyp number on consecutive examinations
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Inability to adequately survey the colon because of multiple polyps
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Following colectomy, continued endoscopic evaluation of the rectum and ileal pouch every 12 months.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3658556608">
         <span class="h2">
          Upper gastrointestinal tract polyps and cancer
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Upper endoscopy starting at the age of 12 years. If polyps are detected, upper endoscopy is repeated annually. In the absence of upper gastrointestinal tract polyps, upper endoscopy can be performed every two to three years [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Baseline examination of the small bowel starting in the teenage years and then repeated periodically based upon the presence of small bowel polyps or symptoms, including anemia or protein-losing enteropathy. The small bowel can be evaluated using wireless capsule endoscopy, small bowel imaging (eg, computed tomography [CT] enterography), or small bowel enteroscopy (eg, double balloon enteroscopy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with advanced dysplasia, gastric cancer, or massive gastric polyposis that cannot be effectively managed endoscopically, complete or partial gastrectomy is warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional details and supporting evidence are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15805.html" rel="external">
          "Juvenile polyposis syndrome", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1102077108">
         <span class="h2">
          Hereditary hemorrhagic telangiectasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants in
         <em>
          SMAD4
         </em>
         can cause HHT, although HHT is more commonly caused by variants in other genes.
        </p>
        <p>
         Individuals with pathogenic variants in
         <em>
          SMAD4
         </em>
         should have an assessment of family history and personal history for clinical manifestations and complications of HHT, including epistaxis, gastrointestinal bleeding, and others. (See
         <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"
         </a>
         .)
        </p>
        <p>
         All symptoms attributable to telangiectasia, arteriovenous malformations (AVMs), or bleeding should be thoroughly evaluated. Decisions regarding screening of asymptomatic individuals, including the specific tests and age at which to initiate them, are best done in consultation with an HHT center and/or facilitated by a clinician with expertise in HHT management. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1434705350">
         <span class="h1">
          IMPLICATIONS OF A NEGATIVE TEST
         </span>
         <span class="headingEndMark">
          —
         </span>
         Negative testing means no pathogenic variants were identified  (
         <a class="graphic graphic_algorithm graphicRef131006" href="/z/d/graphic/131006.html" rel="external">
          algorithm 1
         </a>
         ). However, some tests only evaluate a subset of variants; pathogenic variants might be present in other parts of the gene (if testing was not comprehensive) or in other genes (eg,
         <em>
          BMPR1A
         </em>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a familial
         <em>
          SMAD4
         </em>
         variant is known and the tested individual does not have that variant, usually they can be reassured that they are not at high risk for juvenile polyposis syndrome (JPS) or hereditary hemorrhagic telangiectasia (HHT), with caveats outlined above (see
         <a class="local">
          'How to read the report'
         </a>
         above). However, it is important to provide an individualized risk assessment based on family history and other risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a familial
         <em>
          SMAD4
         </em>
         variant is not known and the results of genetic testing of the presenting (or consulting) patient are negative, the extent of additional testing depends on the personal and family history. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful to determine optimal testing in those with a strong family history of gastrointestinal polyposis or telangiectasia. (See
         <a class="local">
          'Locating an expert'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1468386525">
         <span class="h1">
          IMPLICATIONS OF A VUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history and not the VUS  (
         <a class="graphic graphic_algorithm graphicRef131006" href="/z/d/graphic/131006.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         New information may become available; the testing laboratory or other resources should be consulted periodically for updates (eg, annually).
        </p>
        <p>
         The implications of genetic test results should be discussed with the individual's gastroenterologist, oncologist, or surgeon; in some cases, referral to a specialist in hereditary colorectal cancer syndromes may be appropriate.
        </p>
        <p class="headingAnchor" id="H1215393141">
         <span class="h1">
          CONSIDERATIONS FOR FAMILY MEMBERS
         </span>
        </p>
        <p class="headingAnchor" id="H2253468509">
         <span class="h2">
          Reproductive counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Family planning is appropriate for individuals with a pathogenic or likely pathogenic variant in
         <em>
          SMAD4
         </em>
         who are considering childbearing.
        </p>
        <p>
         Some may elect assisted reproduction (including donor gametes or in vitro fertilization [IVF] with preimplantation genetic testing [PGT]) or prenatal diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3577158096">
         <span class="h2">
          At-risk relatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with a pathogenic variant or likely pathogenic variant in
         <em>
          SMAD4
         </em>
         should inform their at-risk relatives about the importance of genetic counseling and possible testing.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of inheriting or having the variant is typically 50 percent for first-degree relatives. Others at risk may include aunts, uncles, nieces, nephews, and cousins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Usually, the variant segregates on the side of the family with a history of polyposis or gastrointestinal cancer; however, if possible, it is recommended to test a parent or other relative with cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic testing of at-risk relatives may be considered as early as 12 years. Age of polyposis onset for relatives may help guide the timing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Families facing decisions to test minors should meet with a genetic counselor or other health care provider with genetics expertise. If genetic testing is deferred in a child at 50 percent risk, juvenile polyposis syndrome (JPS) screening is recommended until genetic testing is obtained. (See
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing", section on 'Ethical, legal, and psychosocial issues'
         </a>
         and
         <a class="local">
          'Implications of a pathogenic or likely pathogenic variant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2446342527">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H353005643">
         <span class="h2">
          UpToDate topics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Juvenile polyposis syndrome (JPS) – (See
         <a class="medical medical_review" href="/z/d/html/15805.html" rel="external">
          "Juvenile polyposis syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary hemorrhagic telangiectasia (HHT) – (See
         <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variant classification – (See
         <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">
          "Basic genetics concepts: DNA regulation and gene expression", section on 'Clinical classification of pathogenicity'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Terminology – (See
         <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">
          "Genetics: Glossary of terms"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic testing – (See
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic counseling – (See
         <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">
          "Genetic counseling: Family history interpretation and risk assessment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1100375960">
         <span class="h2">
          Locating an expert
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical geneticists – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=130280" target="_blank">
          ACMG
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic counselors – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=130280" target="_blank">
          NSGC
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         National Institutes of Health (NIH) Cancer Genetics
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=130280" target="_blank">
          Services Directory
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HHT Centers of Excellence –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcurehht.org%2Funderstanding-hht%2Fget-support%2Fhht-treatment-centers%2F&amp;token=LSr1gzrB0603EY0icQ2tBZmOhDn5kPfZWpNset6YNAoSeOlEZUOslFUyA22zTDS4gWsFt7CPZ573jlC1gurOU1EWohASQump3UIQIwpoCOU%3D&amp;TOPIC_ID=130280" target="_blank">
          Cure HHT
         </a>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreibman IR, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol 2005; 100:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brosens LA, van Hattem A, Hylind LM, et al. Risk of colorectal cancer in juvenile polyposis. Gut 2007; 56:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latchford AR, Neale K, Phillips RK, Clark SK. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. Dis Colon Rectum 2012; 55:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katabathina VS, Menias CO, Khanna L, et al. Hereditary Gastrointestinal Cancer Syndromes: Role of Imaging in Screening, Diagnosis, and Management. Radiographics 2019; 39:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blatter R, Tschupp B, Aretz S, et al. Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genet Med 2020; 22:1524.
          </a>
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on October 24, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020; 173:989.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 130280 Version 4.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15667510" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The hamartomatous polyposis syndromes: a clinical and molecular review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17303595" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Risk of colorectal cancer in juvenile polyposis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22965402" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25645574" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31373866" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hereditary Gastrointestinal Cancer Syndromes: Role of Imaging in Screening, Diagnosis, and Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32398773" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32398773" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32894695" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
